assess
efficaci
remdesivir
allevi
clinic
sign
merscov
infect
rhesu
macaqu
randomli
assign
three
group
six
anim
three
anim
control
group
treat
mlkg
vehicl
solut
h
merscov
inocul
three
anim
treat
h
post
merscov
inocul
anoth
group
six
rhesu
macaqu
treat
prophylact
h
merscov
inocul
mgkg
remdesivir
one
group
six
anim
treat
therapeut
h
postinocul
merscov
mgkg
remdesivir
treatment
continu
daili
postinocul
dpi
anim
euthan
necropsi
fig
inocul
merscov
day
anim
close
observ
sign
diseas
clinic
score
assign
accord
previous
determin
score
sheet
vehicletr
anim
display
sign
diseas
start
earli
dpi
decreas
appetit
ruffl
fur
vehicletr
anim
respiratori
sign
increas
respir
n
n
inocul
anim
treat
prophylact
remdesivir
show
respiratori
sign
diseas
decreas
appetit
possibl
due
daili
anesthesia
note
five
six
anim
anim
treat
therapeut
remdesivir
display
reduc
appetit
five
six
anim
increas
respir
rate
n
n
n
inocul
observ
reflect
clinic
score
anim
clinic
score
prophylact
treat
anim
statist
significantli
lower
vehicletr
control
anim
dpi
therapeut
treat
anim
dpi
fig
day
clinic
examin
perform
anim
respir
rate
determin
anesthet
anim
clear
increas
respir
rate
vehicletr
anim
fig
respir
rate
prophylact
treat
anim
remain
normal
throughout
studi
although
respir
rate
increas
therapeut
treat
anim
dpi
respir
statist
significantli
lower
vehicletr
control
dpi
fig
examin
day
radiograph
collect
anim
analyz
presenc
infiltr
dpi
onward
lung
infiltr
becam
visibl
xray
si
appendix
fig
dpi
statist
significantli
less
infiltr
lung
anim
treat
prophylact
therapeut
remdesivir
compar
vehicletr
control
anim
fig
dpi
anim
euthan
respiratori
tissu
collect
quantit
analysi
level
viral
rna
qrtpcr
compar
vehicletr
control
anim
prophylact
remdesivir
treatment
result
significantli
lower
level
merscov
replic
lung
lung
viral
load
log
lower
lung
lobe
fig
although
lung
viral
load
averag
lower
individu
lung
lobe
therapeut
treatment
statist
signific
lung
lobe
due
larger
variat
anim
therapeut
treat
group
fig
howev
lung
lobe
combin
lung
viral
load
therapeut
treat
anim
clearli
lower
vehicletr
anim
fig
addit
viral
load
significantli
lower
trachea
bronchi
tonsil
mediastin
lymph
node
anim
treat
prophylact
therapeut
remdesivir
vehicletr
control
anim
fig
si
appendix
fig
viral
rna
detect
kidney
tissu
sampl
si
appendix
fig
upon
necropsi
area
lung
lobe
affect
gross
lesion
estim
boardcertifi
veterinari
pathologist
gross
lung
lesion
present
sever
lung
lobe
vehicletr
control
anim
fig
contrast
gross
lung
lesion
complet
absent
lung
anim
receiv
prophylact
remdesivir
treatment
anim
treat
therapeut
remdesivir
obviou
gross
lesion
present
five
six
anim
howev
total
area
lung
affect
gross
lesion
statist
significantli
smaller
vehicletr
control
anim
fig
addit
sever
histolog
lung
lesion
assess
assign
score
lung
lobe
result
cumul
lung
histolog
score
compar
treatment
group
assess
differ
sever
histolog
lesion
cumul
lung
histolog
score
significantli
lower
anim
treat
prophylact
remdesivir
fig
larg
variat
anim
therapeut
treat
group
meant
lower
averag
histolog
score
reach
statist
signific
fig
histolog
vehicletr
control
anim
develop
degre
pulmonari
patholog
inocul
merscov
lesion
multifoc
frequent
center
termin
bronchiol
consist
minim
mark
interstiti
pneumonia
character
thicken
alveolar
septa
edema
fluid
fibrin
small
moder
number
macrophag
fewer
neutrophil
alveoli
contain
moder
number
pulmonari
macrophag
neutrophil
area
moder
mark
chang
abund
alveolar
edema
fibrin
multifoc
format
hyalin
membran
well
abund
type
ii
pneumocyt
hyperplasia
perivascular
infiltr
inflammatori
cell
multifoc
within
adjac
affect
area
lung
also
observ
fig
contrast
anim
treat
prophylact
remdesivir
essenti
normal
pulmonari
tissu
evid
coronaviru
infect
fig
anim
treat
remdesivir
therapeut
demonstr
variou
level
sever
coronavir
pneumonia
two
six
anim
histolog
evid
pneumonia
detect
three
anim
multifoc
minim
moder
interstiti
pneumonia
observ
like
describ
control
anim
howev
lesion
less
sever
control
wide
distribut
throughout
lung
lobe
one
six
anim
moder
interstiti
pneumonia
indistinguish
vehicletr
control
anim
sever
distribut
immunohistochem
analysi
presenc
merscov
antigen
show
small
number
antigenposit
type
pneumocyt
vehicletr
control
anim
five
six
anim
treat
therapeut
remdesivir
differ
number
distribut
antigenposit
cell
anim
antigen
detect
merscov
antigen
could
detect
anim
treat
prophylact
remdesivir
fig
prophylact
remdesivir
treatment
prevent
clinic
diseas
lung
lesion
rhesu
macaqu
inocul
merscov
strongli
inhibit
merscov
replic
respiratori
tissu
sinc
nosocomi
transmiss
account
approxim
onethird
merscov
case
prophylact
remdesivir
treatment
patient
contact
patient
healthcar
personnel
highrisk
exposur
diagnos
mer
patient
high
risk
develop
sever
mer
due
underli
condit
could
consid
therapeut
remdesivir
treatment
also
provid
clear
clinic
benefit
reduct
clinic
sign
viru
replic
absenc
lung
lesion
two
six
remdesivirtr
anim
reduct
lesion
sever
three
addit
anim
absenc
histolog
lung
lesion
seen
two
six
anim
therapeut
remdesivir
treatment
far
rare
observ
studi
test
efficaci
merscov
antivir
nonhuman
primat
model
shown
one
three
common
marmoset
treat
hyperimmun
plasma
h
inocul
thu
although
hard
compar
differ
studi
due
fact
differ
speci
use
treatment
initi
differ
time
point
inocul
remdesivir
appear
one
promis
antivir
treatment
test
nonhuman
primat
model
date
therapeut
remdesivir
treatment
administ
h
inocul
merscov
although
may
seem
rel
earli
inocul
close
peak
merscov
replic
rhesu
macaqu
model
drug
inhibit
viru
replic
may
littl
use
viru
replic
reach
peak
shown
vitro
howev
consider
number
sever
case
mer
viral
rna
infecti
viru
still
detect
respiratori
tract
sampl
sever
week
onset
symptom
prolong
viru
replic
like
due
presenc
underli
condit
diabet
mellitu
likewis
increas
viru
replic
longer
period
time
observ
immunocompromis
rhesu
macaqu
thu
remdesivir
treatment
could
benefit
patient
diagnos
mer
earli
symptom
onset
may
also
improv
recoveri
patient
sever
case
mer
prolong
viru
replic
occur
human
safeti
data
avail
remdesivir
use
compassion
basi
sever
uniqu
case
ebola
viru
diseas
well
larg
scale
ongo
ebola
viru
outbreak
democrat
republ
congo
around
treat
patient
addit
efficaci
current
test
clinic
trial
ebola
viru
diseas
survivor
prolong
viru
shed
although
efficaci
remdesivir
lower
ebola
viru
trial
differ
antibodi
treatment
test
surviv
increas
compar
overal
surviv
rate
outbreak
taken
togeth
data
present
efficaci
remdesivir
prophylact
therapeut
treatment
regimen
difficulti
coronavirus
acquir
resist
remdesivir
avail
human
safeti
data
warrant
test
efficaci
remdesivir
treatment
context
mer
clinic
trial
result
togeth
replic
inhibit
remdesivir
wide
rang
coronavirus
vitro
vivo
may
indic
util
remdesivir
novel
coronaviru
emerg
wuhan
china
anim
experi
approv
institut
anim
care
use
committe
rocki
mountain
laboratori
nih
carri
certifi
staff
associ
assess
accredit
laboratori
anim
care
intern
accredit
facil
accord
institut
guidelin
anim
use
follow
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
guid
care
use
laboratori
anim
rhesu
macaqu
hous
adjac
individu
primat
cage
allow
social
interact
climatecontrol
room
fix
cycl
dark
anim
monitor
least
twice
daili
throughout
experi
commerci
monkey
chow
treat
fruit
provid
twice
daili
train
personnel
water
avail
ad
libitum
environment
enrich
consist
varieti
human
interact
commerci
toy
video
music
institut
biosafeti
committe
ibc
approv
work
infecti
merscov
strain
condit
sampl
inactiv
perform
accord
ibcapprov
standard
oper
procedur
remov
specimen
high
contain
evalu
effect
remdesivir
treatment
merscov
diseas
outcom
use
rhesu
macaqu
model
merscov
infect
result
transient
lower
respiratori
tract
diseas
rhesu
macaqu
chosen
requir
daili
anesthesia
intraven
iv
inject
perceiv
problemat
altern
nonhuman
primat
model
merscov
infect
common
marmoset
due
small
size
anim
randomli
assign
group
inocul
describ
previous
total
dose
merscov
strain
via
intranas
oral
ocular
intratrach
rout
first
experi
efficaci
prophylact
remdesivir
treatment
test
one
group
six
rhesu
macaqu
male
femal
rhesu
macaqu
avail
supplier
time
studi
treat
mgkg
remdesivir
vehicl
solut
mgml
water
hydrochlor
acid
three
control
rhesu
macaqu
male
receiv
volum
mlkg
vehicl
solut
mgkg
dose
rhesu
macaqu
roughli
equival
daili
dose
use
human
ebola
viru
clinic
trial
treatment
initi
h
viru
inocul
continu
daili
dpi
observ
good
efficaci
remdesivir
upon
prophylact
treatment
second
experi
perform
assess
therapeut
efficaci
one
group
six
rhesu
macaqu
male
treat
mgkg
remdesivir
three
control
rhesu
macaqu
male
receiv
volum
vehicl
solut
due
acut
natur
merscov
model
rhesu
macaqu
therapeut
treatment
initi
h
inocul
merscov
continu
daili
dpi
treatment
deliv
slow
iv
bolu
inject
total
dose
deliv
min
administ
alternatingli
left
right
cephal
saphen
vein
anim
observ
twice
daili
clinic
sign
diseas
use
standard
score
sheet
describ
previous
person
blind
group
assign
anim
assess
anim
throughout
studi
predetermin
endpoint
experi
dpi
clinic
examin
perform
dpi
anesthet
anim
examin
day
clinic
paramet
bodi
weight
respir
rate
collect
well
later
chest
radiograph
chest
radiograph
analyz
boardcertifi
clinic
veterinarian
blind
group
assign
anim
euthanasia
dpi
necropsi
perform
percentag
gross
lung
lesion
score
boardcertifi
veterinari
pathologist
blind
group
assign
anim
sampl
follow
tissu
collect
conjunctiva
nasal
mucosa
mandibular
lymph
node
tonsil
pharynx
trachea
six
lung
lobe
mediastin
lymph
node
liver
spleen
kidney
bladder
histopatholog
analysi
tissu
slide
perform
boardcertifi
veterinari
pathologist
blind
group
assign
anim
vero
passag
kindli
provid
depart
virosci
erasmu
medic
center
rotterdam
netherland
propag
cell
dulbecco
modifi
eagl
medium
dmem
sigma
supplement
fetal
calf
serum
fc
logan
mm
lglutamin
lonza
uml
penicillin
streptomycin
gibco
viru
isol
medium
nextgener
sequenc
merscov
inoculum
reveal
delet
small
percentag
sequenc
cell
maintain
dmem
supplement
fc
mm
lglutamin
uml
penicillin
streptomycin
tissu
mg
homogen
rlt
buffer
rna
extract
use
rneasi
kit
qiagen
accord
manufactur
instruct
detect
viral
rna
rna
use
onestep
realtim
rtpcr
upe
assay
use
rotorgen
probe
kit
qiagen
accord
instruct
manufactur
run
standard
dilut
titer
viru
stock
run
parallel
calcul
equival
sampl
histopatholog
immunohistochemistri
perform
rhesu
macaqu
tissu
fixat
neutralbuff
formalin
embed
paraffin
tissu
section
stain
hematoxylin
eosin
h
e
detect
antigen
immunohistochemistri
perform
use
inhous
rabbit
polyclon
antiserum
primari
antibodi
stain
slide
analyz
boardcertifi
veterinari
pathologist
blind
group
assign
anim
statist
analys
perform
use
graphpad
prism
softwar
version
analysi
three
vehicl
control
anim
first
second
experi
combin
form
one
group
six
anim
data
discuss
made
avail
reader
upon
request
